PFE vs MRK
Pfizer · Merck
| PFE Pfizer Healthcare | MRK Merck Healthcare | |
|---|---|---|
| Market | ||
| Price | $30.52 +1.90% | $149.52 +2.18% |
| Market cap | $174.0B | $368.9B |
| P/E (TTM) | 40.1 | 116.3 |
| Dividend yield | 5.38% | 2.87% |
| 52-week range | $23.62 – $30.67 | $82.01 – $156.92 |
| Our research | ||
| Our view | LONG open | LONG open |
| Articles | 1 | 1 |
| Latest article | Pfizer's Vyndaqel Patent Cliff Just Got Pushed To 2031 — The Market Hasn't Noticed Yet (P… Jun 14, 2026 | Merck (MRK): Revenue Up 5%, But $550M Of Purchase Timing Was About Two-Thirds Of The Incr… Nov 1, 2026 |
| Latest earnings | ||
| Reported | — | Oct 29, 2026 |
| Revenue | — | — |
| EPS | — | $2.04 |
| Guidance | — | Guidance issued |
| Revenue growth, last 4 reports | — | — |
| Topics | ||
| Main topics | ||
| Company page | Company page · Earnings releases | |
Note. Earnings figures are extracted automatically from each company's own release; prices are delayed up to 15 minutes. This comparison is information, not investment advice.